| 0.556 | 0.003 | 0.556 | Estrogen receptor alpha antagonist | | |
| 0.436 | 0.004 | 0.436 | Estrogen antagonist | | |
| 0.446 | 0.04 | 0.446 | Aldehyde oxidase inhibitor | | |
| 0.401 | 0.04 | 0.401 | Spasmolytic | | |
| 0.424 | 0.08 | 0.424 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | | |
| 0.342 | 0.007 | 0.342 | Toll-Like receptor 9 antagonist | | |
| 0.408 | 0.076 | 0.408 | Calcium channel L-type activator | | |
| 0.424 | 0.097 | 0.424 | Caspase 9 stimulant | | |
| 0.325 | 0.005 | 0.325 | Estrogen receptor beta antagonist | | |
| 0.34 | 0.032 | 0.34 | Sigma receptor agonist | | |
| 0.355 | 0.063 | 0.355 | Antithrombotic | | |
| 0.277 | 0.008 | 0.277 | 5 Hydroxytryptamine 3E antagonist | | |
| 0.283 | 0.043 | 0.283 | 5 Hydroxytryptamine 1E antagonist | | |
| 0.245 | 0.022 | 0.245 | Acetylcholinesterase inhibitor | | |
| 0.235 | 0.019 | 0.235 | Toll-Like receptor antagonist | | |
| 0.221 | 0.007 | 0.221 | Estrogen agonist | | |
| 0.23 | 0.017 | 0.23 | Butyrylcholinesterase inhibitor | | |
| 0.237 | 0.027 | 0.237 | Phospholipase A2 inhibitor | | |
| 0.322 | 0.113 | 0.322 | Histamine release inhibitor | | |
| 0.3 | 0.092 | 0.3 | Calcium channel activator | | |
| 0.212 | 0.009 | 0.212 | Dopamine agonist | | |
| 0.231 | 0.034 | 0.231 | Cholinergic | | |
| 0.272 | 0.082 | 0.272 | Hypoxia-inducible factor 1 alpha inhibitor | | |
| 0.188 | 0.011 | 0.188 | Dopamine D1 antagonist | | |
| 0.201 | 0.027 | 0.201 | Alpha adrenoreceptor antagonist | | |
| 0.207 | 0.039 | 0.207 | Proto-oncogene tyrosine-protein kinase Yes inhibitor | | |
| 0.189 | 0.022 | 0.189 | Alpha 1 adrenoreceptor antagonist | | |
| 0.228 | 0.065 | 0.228 | Amyloid beta aggregation inhibitor | | |
| 0.272 | 0.112 | 0.272 | Vasodilator, peripheral | | |
| 0.18 | 0.021 | 0.18 | Dopamine antagonist | | |
| 0.184 | 0.027 | 0.184 | Neuropeptide Y1 antagonist | | |
| 0.187 | 0.03 | 0.187 | DNA intercalator | | |
| 0.189 | 0.033 | 0.189 | 5 Hydroxytryptamine 2 antagonist | | |
| 0.195 | 0.044 | 0.195 | Lipid peroxidase inhibitor | | |
| 0.198 | 0.058 | 0.198 | Amyloid beta precursor protein antagonist | | |
| 0.18 | 0.041 | 0.18 | Bone formation stimulant | | |
| 0.143 | 0.005 | 0.143 | Acetylcholine M5 receptor agonist | | |
| 0.227 | 0.091 | 0.227 | Hypoglycemic | | |
| 0.303 | 0.17 | 0.303 | Apoptosis agonist | | |
| 0.166 | 0.035 | 0.166 | 5 Hydroxytryptamine 2B antagonist | | |
| 0.153 | 0.021 | 0.153 | Transcription factor STAT6 inhibitor | | |
| 0.219 | 0.087 | 0.219 | Antiamyloidogenic | | |
| 0.152 | 0.022 | 0.152 | Dopamine D2 antagonist | | |
| 0.14 | 0.012 | 0.14 | Histamine H2 receptor antagonist | | |
| 0.144 | 0.017 | 0.144 | Toll-Like receptor 3 antagonist | | |
| 0.16 | 0.035 | 0.16 | Alpha 2b adrenoreceptor antagonist | | |
| 0.279 | 0.156 | 0.279 | MAP kinase kinase 6 inhibitor | | |
| 0.151 | 0.028 | 0.151 | Mediator release inhibitor | | |
| 0.253 | 0.132 | 0.253 | Vasodilator, coronary | | |
| 0.149 | 0.028 | 0.149 | Antineoplastic alkaloid | | |
| 0.199 | 0.078 | 0.199 | Neurotrophic factor enhancer | | |
| 0.152 | 0.031 | 0.152 | Alpha 2c adrenoreceptor antagonist | | |
| 0.162 | 0.045 | 0.162 | 5 Hydroxytryptamine antagonist | | |
| 0.149 | 0.032 | 0.149 | Antihistaminic | | |
| 0.132 | 0.017 | 0.132 | Phosphodiesterase 6D inhibitor | | |
| 0.159 | 0.045 | 0.159 | Nav1.6 sodium channel blocker | | |
| 0.142 | 0.029 | 0.142 | Multidrug resistance-associated protein 1 inhibitor | | |
| 0.138 | 0.028 | 0.138 | Prolactin inhibitor | | |
| 0.135 | 0.025 | 0.135 | Alpha 1b adrenoreceptor antagonist | | |
| 0.224 | 0.114 | 0.224 | Gastrin inhibitor | | |
| 0.217 | 0.108 | 0.217 | 5 Hydroxytryptamine release stimulant | | |
| 0.136 | 0.028 | 0.136 | Histamine H1 receptor antagonist | | |
| 0.239 | 0.133 | 0.239 | Cholesterol antagonist | | |
| 0.183 | 0.077 | 0.183 | P-glycoprotein inhibitor | | |
| 0.166 | 0.061 | 0.166 | Acetylcholine M1 receptor antagonist | | |
| 0.107 | 0.005 | 0.107 | Leukotriene A4 hydrolase inhibitor | | |
| 0.149 | 0.05 | 0.149 | Topoisomerase II inhibitor | | |
| 0.14 | 0.045 | 0.14 | Topoisomerase I inhibitor | | |
| 0.129 | 0.035 | 0.129 | Creatine kinase inhibitor | | |
| 0.109 | 0.016 | 0.109 | Toll-Like receptor 7 antagonist | | |
| 0.127 | 0.033 | 0.127 | 5 Hydroxytryptamine 2C antagonist | | |
| 0.128 | 0.036 | 0.128 | Histamine antagonist | | |
| 0.212 | 0.121 | 0.212 | Transcription factor STAT inhibitor | | |
| 0.12 | 0.03 | 0.12 | Histamine N-methyltransferase inhibitor | | |
| 0.163 | 0.073 | 0.163 | Neurotensin receptor agonist | | |
| 0.142 | 0.053 | 0.142 | Anesthetic local | | |
| 0.111 | 0.023 | 0.111 | Dopamine D4 antagonist | | |
| 0.116 | 0.03 | 0.116 | Alpha 1a adrenoreceptor antagonist | | |
| 0.165 | 0.079 | 0.165 | Antipruritic | | |
| 0.154 | 0.069 | 0.154 | NOS3 expression enhancer | | |
| 0.225 | 0.142 | 0.225 | Ca(v)3.3 blocker | | |
| 0.259 | 0.175 | 0.259 | Analgesic | | |
| 0.147 | 0.066 | 0.147 | Sphingosine 1-phosphate receptor 5 antagonist | | |
| 0.149 | 0.069 | 0.149 | Protein kinase stimulant | | |
| 0.209 | 0.131 | 0.209 | Lipoxygenase inhibitor | | |
| 0.151 | 0.073 | 0.151 | Insulin secretagoues | | |
| 0.103 | 0.025 | 0.103 | Leukotriene synthesis inhibitor | | |
| 0.085 | 0.011 | 0.085 | Calcium channel P-type blocker | | |
| 0.101 | 0.028 | 0.101 | Interferon agonist | | |
| 0.227 | 0.154 | 0.227 | Sodium/bile acid cotransporter inhibitor | | |
| 0.217 | 0.146 | 0.217 | Prostaglandin dehydrogenase inhibitor | | |
| 0.116 | 0.047 | 0.116 | Antiadrenergic | | |
| 0.241 | 0.172 | 0.241 | 15-Lipoxygenase inhibitor | | |
| 0.096 | 0.027 | 0.096 | CC chemokine 5 receptor agonist | | |
| 0.141 | 0.074 | 0.141 | MAP3K9 inhibitor | | |
| 0.087 | 0.02 | 0.087 | 5 Hydroxytryptamine 5A antagonist | | |
| 0.158 | 0.091 | 0.158 | Tumour necrosis factor antagonist | | |
| 0.113 | 0.047 | 0.113 | Adrenaline antagonist | | |
| 0.126 | 0.061 | 0.126 | Acetylcholine muscarinic antagonist | | |
| 0.133 | 0.07 | 0.133 | Nav1.2 sodium channel blocker | | |
| 0.106 | 0.044 | 0.106 | 5 Hydroxytryptamine 2A antagonist | | |
| 0.156 | 0.093 | 0.156 | Catenin beta inhibitor | | |
| 0.087 | 0.025 | 0.087 | Peroxisome proliferator-activated receptor gamma antagonist | | |
| 0.175 | 0.117 | 0.175 | Cyclic AMP phosphodiesterase inhibitor | | |
| 0.095 | 0.038 | 0.095 | Macrophage migration inhibitory factor inhibitor | | |
| 0.064 | 0.009 | 0.064 | GABA uptake inhibitor | | |
| 0.204 | 0.15 | 0.204 | Thyroid hormone beta antagonist | | |
| 0.124 | 0.072 | 0.124 | MAO inhibitor | | |
| 0.069 | 0.018 | 0.069 | 5 Hydroxytryptamine 4 antagonist | | |
| 0.099 | 0.049 | 0.099 | Alpha 2 adrenoreceptor antagonist | | |
| 0.055 | 0.007 | 0.055 | 1-Alkyl-2-acetylglycerophosphocholine esterase inhibitor | | |
| 0.068 | 0.02 | 0.068 | Plasminogen activator inhibitor antagonist | | |
| 0.226 | 0.178 | 0.226 | GABA C receptor rho-3 antagonist | | |
| 0.066 | 0.019 | 0.066 | Dopamine D2 agonist | | |
| 0.06 | 0.014 | 0.06 | Dopamine D3 agonist | | |
| 0.096 | 0.05 | 0.096 | Phosphodiesterase I inhibitor | | |
| 0.183 | 0.137 | 0.183 | Interleukin agonist | | |
| 0.063 | 0.018 | 0.063 | Alpha 1L adrenoreceptor antagonist | | |
| 0.088 | 0.043 | 0.088 | Transforming growth factor beta 3 antagonist | | |
| 0.07 | 0.026 | 0.07 | 5 Hydroxytryptamine 5 antagonist | | |
| 0.087 | 0.043 | 0.087 | Alpha 2a adrenoreceptor antagonist | | |
| 0.067 | 0.024 | 0.067 | Sphingosine kinase 2 inhibitor | | |
| 0.138 | 0.096 | 0.138 | Ca2+/calmodulin-dependent protein kinase kinase B inhibitor | | |
| 0.072 | 0.032 | 0.072 | Interferon inducer | | |
| 0.134 | 0.095 | 0.134 | Thrombolytic | | |
| 0.083 | 0.043 | 0.083 | Telomerase inhibitor | | |
| 0.16 | 0.12 | 0.16 | Insulin sensitizer | | |
| 0.065 | 0.025 | 0.065 | Sigma receptor antagonist | | |
| 0.201 | 0.162 | 0.201 | Thyroid hormone antagonist | | |
| 0.058 | 0.02 | 0.058 | Dopamine D5 antagonist | | |
| 0.097 | 0.059 | 0.097 | Interleukin 12 antagonist | | |
| 0.101 | 0.064 | 0.101 | Gastric antisecretory | | |
| 0.121 | 0.084 | 0.121 | Interleukin 4 antagonist | | |
| 0.08 | 0.048 | 0.08 | Analgesic, opioid | | |
| 0.125 | 0.093 | 0.125 | Farnesoid X receptor antagonist | | |
| 0.077 | 0.046 | 0.077 | Phosphodiesterase VI inhibitor | | |
| 0.248 | 0.216 | 0.248 | Cyclophilin D inhibitor | | |
| 0.089 | 0.058 | 0.089 | Opioid antagonist | | |
| 0.103 | 0.072 | 0.103 | Protein kinase C gamma inhibitor | | |
| 0.059 | 0.028 | 0.059 | Dopamine D4 agonist | | |
| 0.06 | 0.03 | 0.06 | 5 Hydroxytryptamine 7 agonist | | |
| 0.042 | 0.012 | 0.042 | Sigma 2 receptor antagonist | | |
| 0.04 | 0.011 | 0.04 | Estrogen-related receptor beta antagonist | | |
| 0.161 | 0.132 | 0.161 | Free radical scavenger | | |
| 0.083 | 0.054 | 0.083 | Adrenaline agonist | | |
| 0.109 | 0.084 | 0.109 | Cholinergic antagonist | | |
| 0.081 | 0.056 | 0.081 | Opioid kappa receptor antagonist | | |
| 0.064 | 0.039 | 0.064 | Phosphodiesterase 1C inhibitor | | |
| 0.106 | 0.084 | 0.106 | Sphingosine 1-phosphate receptor 2 agonist | | |
| 0.166 | 0.146 | 0.166 | Antioxidant | | |
| 0.059 | 0.039 | 0.059 | Sphingosine 1-phosphate receptor 3 antagonist | | |
| 0.105 | 0.086 | 0.105 | Acetylcholine antagonist | | |
| 0.059 | 0.042 | 0.059 | Acetylcholine M3 receptor antagonist | | |
| 0.063 | 0.046 | 0.063 | Beta 3 adrenoreceptor antagonist | | |
| 0.095 | 0.078 | 0.095 | Beta glucuronidase inhibitor | | |
| 0.027 | 0.011 | 0.027 | Dopamine D1 agonist | | |
| 0.054 | 0.039 | 0.054 | Thromboxane synthase inhibitor | | |
| 0.129 | 0.115 | 0.129 | Melanin inhibitor | | |
| 0.122 | 0.11 | 0.122 | Heat shock protein 90 antagonist | | |
| 0.084 | 0.072 | 0.084 | MAO B inhibitor | | |
| 0.056 | 0.044 | 0.056 | Alpha 1d adrenoreceptor antagonist | | |
| 0.057 | 0.045 | 0.057 | Sphingosine kinase inhibitor | | |
| 0.06 | 0.049 | 0.06 | Beta 2 adrenoreceptor agonist | | |
| 0.066 | 0.055 | 0.066 | HIV-1 integrase inhibitor | | |
| 0.103 | 0.093 | 0.103 | Aldehyde dehydrogenase inhibitor | | |
| 0.061 | 0.052 | 0.061 | 5 Hydroxytryptamine 1A antagonist | | |
| 0.047 | 0.039 | 0.047 | Cannabinoid CB2 receptor antagonist | | |
| 0.033 | 0.024 | 0.033 | Estrogen receptor alpha agonist | | |
| 0.108 | 0.103 | 0.108 | Calcium channel blocker | | |
| 0.055 | 0.05 | 0.055 | Phosphodiesterase 1B inhibitor | | |
| 0.09 | 0.085 | 0.09 | AMP-activated protein kinase stimulant | | |
| 0.088 | 0.084 | 0.088 | Nav1.1 sodium channel blocker | | |
| 0.18 | 0.177 | 0.18 | Tyrosine 3 hydroxylase inhibitor | | |
| 0.058 | 0.056 | 0.058 | Opioid mu receptor antagonist | | |
| 0.027 | 0.025 | 0.027 | Prostaglandin EP3 antagonist | | |
| 0.075 | 0.073 | 0.075 | Caspase 7 inhibitor | | |
| 0.063 | 0.061 | 0.063 | 5 Hydroxytryptamine 1 antagonist | | |
| 0.054 | 0.052 | 0.054 | Acetylcholine M5 receptor antagonist | | |